The new patent entitled, ‘Deep Draw Container Forming Method,’ covers manufacturing technology of VersiDoser and VRx2 drug and biologic delivery systems.
Mystic claims its delivery platforms offer preservative free unit dose packaging and devices for delivery of ophthalmic and intranasal drugs and biologics.
Mystic president and CEO Timothy Sullivan said unit dose packaging combined with their self administered delivery systems set a new standard for improving patient compliance and treatment outcomes.
"With optimized VersiDoser and VRx2 delivery systems, patients can precisely and consistently self-administer daily medications to the eye, nose, mouth, ear or topically to the skin," Sullivan said.